Extracellular cathepsin S and intracellular caspase 1 activation are surrogate biomarkers of particulate-induced lysosomal disruption in macrophages

Particle and Fibre Toxicology

Volumn 13, Issue 1, 2016, Pages

  Hughes, Caroline S ^a   Colhoun, Liza M ^a   Bains, Baljinder K ^a   Kilgour, Joanne D ^b   Burden, Roberta E ^a   Burrows, James F ^a   Lavelle, Ed C ^c   Gilmore, Brendan F ^a   Scott, Christopher J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Affinity binding probes; Caspase 1; Cathepsin S; IL 1 ; Nanoparticles; Proteolytic activity; Toxicity

Indexed keywords

BIOLOGICAL MARKER; CATHEPSIN S; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; NANOPARTICLE; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; CATHEPSIN; DIPEPTIDE; IL1B PROTEIN, MOUSE; LEUCYL-LEUCINE-METHYL ESTER; PARTICULATE MATTER; POLYSTYRENE DERIVATIVE; SILICON DIOXIDE;

ACIDIFICATION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BONE MARROW DERIVED MACROPHAGE; CELL DISRUPTION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; LYSOSOME; MACROPHAGE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; ENZYME SPECIFICITY; ENZYMOLOGY; GENETICS; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; KINETICS; KNOCKOUT MOUSE; METABOLISM; PARTICULATE MATTER; PATHOLOGY; PRIMARY CELL CULTURE; PROCEDURES; PROTEIN DEGRADATION; TOXICITY; TOXICITY TESTING;

ALUM COMPOUNDS; ANIMALS; BIOMARKERS; CASPASE 1; CATHEPSINS; CELLS, CULTURED; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-1BETA; KINETICS; LYSOSOMES; MACROPHAGES, PERITONEAL; MICE, INBRED C57BL; MICE, KNOCKOUT; NANOPARTICLES; PARTICULATE MATTER; POLYSTYRENES; PRIMARY CELL CULTURE; PROTEOLYSIS; SILICON DIOXIDE; SUBSTRATE SPECIFICITY; TOXICITY TESTS;

EID: 84964407517     PISSN: None     EISSN: 17438977     Source Type: Journal    
DOI: 10.1186/s12989-016-0129-5     Document Type: Article

References (49)

1. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med. 1998;157:1666-80.
2. Li JJ, Muralikrishnan S, Ng CT, et al. Nanoparticle-induced pulmonary toxicity. Exp Biol Med (Maywood). 2010;235:1025-33.
3. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81:1-5.
4. Cassel SL, Eisenbarth SC, Iyer SS, et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci U S A. 2008;105:9035-40.
5. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720-32.
6. Thornberry NA, Bull HG, Calaycay JR, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992;356:768-74.
7. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 2007;14:10-22.
8. Darisipudi MN, Thomasova D, Mulay SR, et al. Uromodulin triggers IL-1beta-dependent innate immunity via the NLRP3 inflammasome. J Am Soc Nephrol. 2012;23:1783-9.
9. Dostert C, Petrilli V, Van Bruggen R, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320:674-7.
10. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease. Nature. 2010;464:1357-61.
11. Eisenbarth SC, Colegio OR, O'Connor W, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453:1122-6.
12. Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9:857-65.
13. Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9:847-56.
14. Lima Jr H, Jacobson LS, Goldberg MF, et al. Role of lysosome rupture in controlling Nlrp3 signaling and necrotic cell death. Cell Cycle. 2013;12:1868-78.
15. Sandberg WJ, Lag M, Holme JA, et al. Comparison of non-crystalline silica nanoparticles in IL-1beta release from macrophages. Part Fibre Toxicol. 2012;9:32,8977-9-32.
16. Fonovic M, Turk B. Cysteine cathepsins and their potential in clinical therapy and biomarker discovery. Proteomics Clin Appl. 2014;8:416-26.
17. Hughes CS, Burden RE, Gilmore BF, Scott CJ. Strategies for detection and quantification of cysteine cathepsins-evolution from bench to bedside. Biochimie. 2016;122:48-61.
18. Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene. 2008;27:6434-51.
19. Lin Y, Epstein DL, Liton PB. Intralysosomal iron induces lysosomal membrane permeabilization and cathepsin D-mediated cell death in trabecular meshwork cells exposed to oxidative stress. Invest Ophthalmol Vis Sci. 2010;51:6483-95.
20. Ono K, Kim SO, Han J. Susceptibility of lysosomes to rupture is a determinant for plasma membrane disruption in tumor necrosis factor alpha-induced cell death. Mol Cell Biol. 2003;23:665-76.
21. Fonovic M, Bogyo M. Activity-based probes as a tool for functional proteomic analysis of proteases. Expert Rev Proteomics. 2008;5:721-30.
22. Powers JC, Asgian JL, Ekici OD, James KE. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem Rev. 2002;102:4639-750.
23. Jordans S, Jenko-Kokalj S, Kuhl NM, et al. Monitoring compartment-specific substrate cleavage by cathepsins B, K, L, and S at physiological pH and redox conditions. BMC Biochem. 2009;10:23,2091-10-23.
24. Chen RP, Ren A, Ye SD. Correlation between serum cathepsin S and insulin resistance in type 2 diabetes. Exp Ther Med. 2013;6:1237-42.
25. Liu J, Ma L, Yang J, et al. Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis. 2006;186:411-9.
26. Qin Y, Yang Y, Liu R, et al. Combined Cathepsin S and hs-CRP predicting inflammation of abdominal aortic aneurysm. Clin Biochem. 2013;46:1026-9.
27. Rintahaka J, Lietzen N, Ohman T, et al. Recognition of cytoplasmic RNA results in cathepsin-dependent inflammasome activation and apoptosis in human macrophages. J Immunol. 2011;186:3085-92.
28. Baroja-Mazo A, Martin-Sanchez F, Gomez AI, et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol. 2014;15:738-48.
29. Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun. 2005;73:1907-16.
30. Davis GS, Pfeiffer LM, Hemenway DR. Persistent overexpression of interleukin-1beta and tumor necrosis factor-alpha in murine silicosis. J Environ Pathol Toxicol Oncol. 1998;17:99-114.
31. Srivastava KD, Rom WN, Jagirdar J, et al. Crucial role of interleukin-1beta and nitric oxide synthase in silica-induced inflammation and apoptosis in mice. Am J Respir Crit Care Med. 2002;165:527-33.
32. Piguet PF, Vesin C, Grau GE, Thompson RC. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine. 1993;5:57-61.
33. Shi GP, Webb AC, Foster KE, et al. Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J Biol Chem. 1994;269:11530-6.
34. Riese RJ, Wolf PR, Bromme D, et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity. 1996;4:357-66.
35. Park B, Brinkmann MM, Spooner E, et al. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat Immunol. 2008;9:1407-14.
36. Pozgan U, Caglic D, Rozman B, et al. Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol Chem. 2010;391:571-9.
37. Sukhova GK, Zhang Y, Pan J, et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor deficient mice. J Clin Invest. 2003;111:897-906.
38. Wilkinson RD, Williams R, Scott CJ, Burden RE. Cathepsin S: therapeutic, diagnostic and prognostic potential. Biol Chem. 2015;398:867-82.
39. Zheng T, Kang MJ, Crothers K, et al. Role of cathepsin S-dependent epithelial cell apoptosis in IFN-gamma-induced alveolar remodeling and pulmonary emphysema. J Immunol. 2005;174:8106-15.
40. Turk B, Turk D, Salvesen GS. Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr Pharm Des. 2002;8:1623-37.
41. Hanamsagar R, Torres V, Kielian T. Inflammasome activation and IL-1beta/IL-18 processing are influenced by distinct pathways in microglia. J Neurochem. 2011;119:736-48.
42. Kono H, Orlowski GM, Patel Z, Rock KL. The IL-1-dependent sterile inflammatory response has a substantial caspase-1-independent component that requires cathepsin C. J Immunol. 2012;189:3734-40.
43. Sharp FA, Ruane D, Claass B, et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci. 2009;106:870-5.
44. Orlowski GM, Colbert JD, Sharma S, et al. Multiple Cathepsins Promote Pro-IL-1beta Synthesis and NLRP3-Mediated IL-1beta Activation. J Immunol. 2015;195:1685-97.
45. Oleszycka E, Moran HB, Tynan GA, et al. IL-1alpha and inflammasome-independent IL-1beta promote neutrophil infiltration following alum vaccination. FEBS J. 2016;283:9-24.
46. Oresic Bender K, Ofori L, van der Linden WA, et al. Design of a highly selective quenched activity-based probe and its application in dual color imaging studies of cathepsin s activity localization. J Am Chem Soc. 2015;137:4771-7.
47. Caglic D, Globisch A, Kindermann M, et al. Functional in vivo imaging of cysteine cathepsin activity in murine model of inflammation. Bioorg Med Chem. 2011;19:1055-61.
48. Ben-Aderet L, Merquiol E, Fahham D, et al. Detecting cathepsin activity in human osteoarthritis via activity-based probes. Arthritis Res Ther. 2015;17:69,015-0586-5.
49. Spence S, Greene MK, Fay F, et al. Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation. Sci Transl Med. 2015;7:303ra140.